Prime Medicine, Inc. (PRME)
(Delayed Data from NSDQ)
$4.67 USD
+0.66 (16.46%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $4.99 +0.32 (6.85%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PRME 4.67 +0.66(16.46%)
Will PRME be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRME
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
PRME: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Other News for PRME
Upper Bollinger Band Walk appears for PRME after 1.47% move
NR7 appears for PRME after 0.25% move
Prime Drink Group Granted Extension for Financial Filings
Stochastic Sell Signal appears for PRME after 4.88% move
PRME forms Bearish Engulfing on September 10